BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/8/2022 12:06:56 PM | Browse: 398 | Download: 868
 |
Received |
|
2021-12-06 13:56 |
|
Peer-Review Started |
|
2021-12-06 13:58 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-01-18 01:17 |
|
Revised |
|
2022-01-26 15:00 |
|
Second Decision |
|
2022-02-24 06:10 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-02-27 19:07 |
|
Articles in Press |
|
2022-02-27 19:07 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-03-27 11:44 |
|
Publish the Manuscript Online |
|
2022-04-08 12:06 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hang-Ping Wei, Jie Mao and Zhu-Liang Hu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Zhu-Liang Hu, Doctor, Deputy Director, Department of Medical Oncology, Dongyang Hospital Affiliated to Wenzhou Medical University, No. 60 West Wuning Road, Dongyang 322100, Zhejiang Province, China. applewhp1988@163.com |
| Key Words |
Apatinib; Renal cell carcinoma; Targeted therapy; Palliative treatment; Case report |
| Core Tip |
Apatinib, an orally bioavailable small-molecule receptor tyrosine kinase inhibitor, is typically used in the treatment of partial solid tumours. Here, we report a case of advanced renal cell carcinoma (RCC) with multiple metastases (Stage IV) in a 48-year-old man with an extremely poor general status (Karnofsky 30%). Due to his intolerance to pazopanib (patient developed oral mucositis), we attempted targeted treatment with apatinib, at a dose of 250 mg once daily (from April 2018). This led to an excellent recovery response, realising an approximately 32 mo progression-free survival. This case suggests that apatinib, like other multi-target drugs, may be used as a first-line therapeutic treatment for advanced RCC. |
| Publish Date |
2022-04-08 12:06 |
| Citation |
Wei HP, Mao J, Hu ZL. Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report. World J Clin Cases 2022; 10(11): 3593-3600 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i11/3593.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i11.3593 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
